Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Case Report

Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab

Author(s): Carlos A. Canas*, Fabio Bonilla-Abadia, Katherine Vallejo, Hector M. Rengifo, Marco A. Gallon and Gabriel J. Tobon

Volume 18, Issue 6, 2018

Page: [665 - 667] Pages: 3

DOI: 10.2174/1871530318666180702150243

Price: $65

Abstract

Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6).

Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.

Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.

Conclusion: Tocilizumab could be an optional treatment in patients with TAO.

Keywords: Thyroid-associated ophthalmopathy, Graves` associated ophthalmopathy, tocilizumab, IL-6, extrathyroidal manifestation, infiltrating cytokines.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy